304 related articles for article (PubMed ID: 16458553)
1. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review.
Sadowska AM; Manuel-Y-Keenoy B; De Backer WA
Pulm Pharmacol Ther; 2007; 20(1):9-22. PubMed ID: 16458553
[TBL] [Abstract][Full Text] [Related]
2. N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease.
Sadowska AM
Ther Adv Respir Dis; 2012 Jun; 6(3):127-35. PubMed ID: 22361928
[TBL] [Abstract][Full Text] [Related]
3. [Anti-inflammatory efficacy of N-acetylcysteine and therapeutic usefulness].
Gillissen A
Pneumologie; 2011 Sep; 65(9):549-57. PubMed ID: 21761386
[TBL] [Abstract][Full Text] [Related]
4. Oxidation pathway and exacerbations in COPD: the role of NAC.
Matera MG; Calzetta L; Cazzola M
Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
[TBL] [Abstract][Full Text] [Related]
5. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
Tse HN; Tseng CZ
Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
[TBL] [Abstract][Full Text] [Related]
6. Role of N-acetylcysteine in the management of COPD.
Sadowska AM; Verbraecken J; Darquennes K; De Backer WA
Int J Chron Obstruct Pulmon Dis; 2006; 1(4):425-34. PubMed ID: 18044098
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.
Cazzola M; Calzetta L; Facciolo F; Rogliani P; Matera MG
Respir Res; 2017 Jan; 18(1):26. PubMed ID: 28118826
[TBL] [Abstract][Full Text] [Related]
8. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
[TBL] [Abstract][Full Text] [Related]
9. [N-acetylcysteine: a functional oxygen radical scavenger in vitro and ex vivo in monocytes and neutrophilic granulocytes of patients with COPD].
Jaworska M; Gillissen A; Schärling B; Wickenburg D; Schultze-Werninghaus G
Pneumologie; 1995 Oct; 49(10):539-45. PubMed ID: 8584524
[TBL] [Abstract][Full Text] [Related]
10. Oral N-acetylcysteine attenuates pulmonary emphysema and alveolar septal cell apoptosis in smoking-induced COPD in rats.
Cai S; Chen P; Zhang C; Chen JB; Wu J
Respirology; 2009 Apr; 14(3):354-9. PubMed ID: 19341424
[TBL] [Abstract][Full Text] [Related]
11. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.
Cazzola M; Page CP; Wedzicha JA; Celli BR; Anzueto A; Matera MG
Respir Res; 2023 Jul; 24(1):194. PubMed ID: 37517999
[TBL] [Abstract][Full Text] [Related]
12. Lead induced oxidative stress and its recovery following co-administration of melatonin or N-acetylcysteine during chelation with succimer in male rats.
Flora SJ; Pande M; Kannan GM; Mehta A
Cell Mol Biol (Noisy-le-grand); 2004; 50 Online Pub():OL543-51. PubMed ID: 15555419
[TBL] [Abstract][Full Text] [Related]
13. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits.
Rushworth GF; Megson IL
Pharmacol Ther; 2014 Feb; 141(2):150-9. PubMed ID: 24080471
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine.
Santus P; Corsico A; Solidoro P; Braido F; Di Marco F; Scichilone N
COPD; 2014 Dec; 11(6):705-17. PubMed ID: 24787454
[TBL] [Abstract][Full Text] [Related]
15. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease.
Calzetta L; Matera MG; Rogliani P; Cazzola M
Expert Rev Respir Med; 2018 Aug; 12(8):693-708. PubMed ID: 29972340
[TBL] [Abstract][Full Text] [Related]
16. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
Fowdar K; Chen H; He Z; Zhang J; Zhong X; Zhang J; Li M; Bai J
Heart Lung; 2017; 46(2):120-128. PubMed ID: 28109565
[TBL] [Abstract][Full Text] [Related]
17. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease.
Kasielski M; Nowak D
Respir Med; 2001 Jun; 95(6):448-56. PubMed ID: 11421501
[TBL] [Abstract][Full Text] [Related]
18. N-acetylcysteine expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic acid-induced colitis in rats.
Uraz S; Tahan G; Aytekin H; Tahan V
Scand J Clin Lab Invest; 2013 Feb; 73(1):61-6. PubMed ID: 23110331
[TBL] [Abstract][Full Text] [Related]
19. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation.
Calzetta L; Rogliani P; Facciolo F; Rinaldi B; Cazzola M; Matera MG
Biomed Pharmacother; 2018 Jul; 103():1-8. PubMed ID: 29635121
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
